Skip to main content

Advertisement

SpringerLink
Log in

Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes

  • Original Paper
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Exenatide is a new injectable medication for the treatment of hyperglycemia in type 2 diabetes. Due to limited information of exenatide use in Asians and Pacific Islanders (API), we retrospectively reviewed API patients’ responses to exenatide treatment and compared the efficacy and safety of treatment to Caucasian patients. A total of 92 patients (70 API, 21 Caucasians, and 1 Hispanic) with type 2 diabetes were treated with exenatide. In all patients, there was a significant decrease in A1c level, BMI, and weight after 6 months of exenatide treatment (A1c from 8.63 ± 1.46 to 8.23 ± 1.46; P = 0.03, BMI from 34.54 ± 7.07 to 32.14 ± 6.41; P < 0.01, and weight from 215.24 ± 52.04 to 202.50 ± 49.90; P < 0.01 at 95% CI, N = 51). However, differences in mean change of A1c level, BMI, and weight between API and Caucasian patients were not observed at 3 and 6 months of treatment. Side effects and discontinuation of exenatide treatment between API and Caucasian patients were similar. In conclusion, exenatide is an effective anti-hyperglycemic agent in API patients with responses similar to that observed for Caucasian patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. K. Dungan, J.B. Buse, Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clin. Diabetes 23, 56–62 (2005)

    Article  Google Scholar 

  2. M.-B. Toft-Nielsen, M.B. Damholt, S. Madsbad, L.M. Hilsted, T.E. Hughes, B.K. Michelsen, J.J. Holst, Determinants of the impaired secretion of glucagons-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. 86(8), 3717–3723 (2001)

    Article  CAS  Google Scholar 

  3. M.-B. Toft-Nielsen, S. Madsbad, J.J. Holst, Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J. Clin. Endocrinol. 86(8), 3853–3860 (2001)

    Article  CAS  Google Scholar 

  4. D.J. Drucker, M.A. Nauck, The incretin system: glucacon-like peptide-1 receptor agonists and dipeptyl peptidase-4 inhibitors in type 2 diabetes Lancet 368(9548), 1696–1705 (2006)

    Article  CAS  PubMed  Google Scholar 

  5. J. Schirra, B. Goke, The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul. Pept. 128, 109–115 (2005)

    Article  CAS  PubMed  Google Scholar 

  6. R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman, A.D. Baron, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28(5), 1092–1100 (2005)

    Article  CAS  PubMed  Google Scholar 

  7. D.M. Kendall, M.C. Riddle, J. Rosenstock, D. Zhuang, D.D. Kim, M.S. Fineman, A.D. Baron, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28(5), 1083–1091 (2005)

    Article  CAS  PubMed  Google Scholar 

  8. J.B. Buse, R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, A.D. Baron, Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27(11), 2628–2635 (2004)

    Article  CAS  PubMed  Google Scholar 

  9. J.A. Loh, S.C. Clement, Efficacy of exenatide therapy over 12 months in a “real world” setting (Abstract). Diabetes 56(supplement1) A512; 570-P. (2007)

    Google Scholar 

  10. A.B. King, G. Wolfe, S. Healy, Clinical observations of exenatide treatment. Diabetes Care 29, 1984 (2006)

    Article  PubMed  Google Scholar 

  11. R.J. Heine, L.F. Van Gaal, D. Johns, M.J. Mihm, M.H. Widel, R.G. Brodows, GWAA study group, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann. Intern. Med. 143, 559–569 (2005)

    CAS  PubMed  Google Scholar 

  12. L. Blonde, E.J. Klein, J. Han, B. Zhang, S.M. Mac, T.H. Poon, K.L. Taylor, M.E. Trautmann, D.D. Kim, D.M. Kendal, Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. 8, 436–447 (2006)

    Article  CAS  PubMed  Google Scholar 

  13. M.A. Nauck, S. Duran, D. Kim, D. Johns, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 50, 259–267 (2007)

    Article  CAS  PubMed  Google Scholar 

  14. M.C. Riddle, R.R. Henry, T.H. Poon, B. Zhang, S.M. Mac, J.H. Holcombe, D.D. Kim, D.G. Maggs, Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab. Res. Rev. 22(6), 483–491 (2006)

    Article  CAS  PubMed  Google Scholar 

  15. R.E. Ratner, D. Maggs, L.L. Nielsen, A.H. Stonehouse, T. Poon, B. Zhang, T.A. Bicsak, R.G. Brodows, D.D. Kim, Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 8(4), 419–428 (2006)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, John A. Burns School of Medicine University of Hawaii-Manoa, 677 Ala Moana Blvd, 1024, Honolulu, Hawaii, 96813

    Nalurporn Chokrungvaranon, Teera Chentanez & Richard F. Arakaki

Authors
  1. Nalurporn Chokrungvaranon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teera Chentanez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard F. Arakaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard F. Arakaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chokrungvaranon, N., Chentanez, T. & Arakaki, R.F. Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes. Endocr 32, 311–316 (2007). https://doi.org/10.1007/s12020-008-9042-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-008-9042-5

Keywords

Search

Navigation